Latest news with #NUTX
Yahoo
15-05-2025
- Business
- Yahoo
Nutex Health Inc (NUTX) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Expansion ...
Release Date: May 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Nutex Health Inc (NASDAQ:NUTX) reported a significant increase in total revenue for Q1 2025, reaching $211.8 million, a 214% increase from the previous year. The company achieved a 20.5% increase in total patient visits, indicating strong demand for its services. Net income attributable to Nutex Health Inc (NASDAQ:NUTX) was $14.6 million, a substantial improvement from a loss in the previous year. The arbitration process has been successful, with an 80% win rate, leading to increased facility collections by 200-300% compared to initial insurance payments. Nutex Health Inc (NASDAQ:NUTX) plans to open three additional hospitals in 2025, expanding its microhospital model in high-demand markets. The arbitration process, while beneficial, involves high monetary costs and extended time to receive payments, which could impact cash flow. Despite improvements, the company is not yet at a steady state with its arbitration process, indicating potential volatility in future quarters. Labor costs increased by 29%, driven by higher volumes and the opening of new hospitals, which could pressure margins. The company faces challenges in expanding its hospital network due to the time-intensive nature of building new facilities from the ground up. There is no current penalty for insurance companies that delay payments, which could affect the timeliness of revenue realization. Warning! GuruFocus has detected 8 Warning Signs with NUTX. Q: Can you provide more clarity on the arbitration process and its impact on cash flow? A: John Bates, CFO, explained that while they are still in the early stages of the arbitration process, they are beginning to see more predictable patterns. The reimbursement rates have shown improvement, and while they are not yet at a steady state, the trend is positive. The company expects further clarity as they continue to gather data over the next few quarters. Q: With the cash reserves growing, what are your plans for capital deployment? A: Tom Vo, CEO, mentioned that they are considering several options, including opening new hospitals, investing in population health, and potentially acquiring smaller hospitals. They are also considering shareholder returns through dividends or share buybacks, but the focus remains on maximizing shareholder value. Q: How is the addition of new arbitrators expected to impact the arbitration process? A: John Bates, CFO, noted that the addition of new arbitrators is expected to help alleviate the backlog in the arbitration process. This should improve the timeliness of payments and overall efficiency, which is beneficial for the company. Q: Are you operating at a steady run rate in terms of acuity mix and inpatient volume? A: Tom Vo, CEO, and Josh Deilio, COO, indicated that while they have room to grow in inpatient capacity, they are adding specialists to manage more complex cases. They expect continued growth in acuity and inpatient volumes as they enhance their capabilities. Q: Is there a penalty payment included in arbitration settlements, and how might this affect future revenue comparisons? A: John Bates, CFO, clarified that currently, there is no penalty for late payments in arbitration settlements. However, proposed legislation could introduce penalties, which would improve payment timeliness. This change could impact future revenue comparisons if implemented. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-04-2025
- Business
- Yahoo
Why Nutex Health Inc. (NUTX) is Surging in 2025
We recently published a list of . In this article, we are going to take a look at where Nutex Health Inc. (NASDAQ:NUTX) stands against other healthcare stocks that are surging in 2025. After lagging behind the broader market in 2024, many healthcare stocks are making a comeback this year. Healthcare spending has been continuously soaring and is projected to do so in the coming years due to demographic tailwinds. The industry now accounts for a fifth of the U.S. economy, and it's a good idea to have exposure to it. Most executives now hold a favorable view of the industry's prospects, a notable increase from 52% just a year ago. Moreover, it's an industry that is more insulated from tariffs and macro risks. Of course, the top gainers here are not defensive healthcare stocks, but it's still worth looking into the winners here if you are chasing potential multibaggers. Even during bear markets, there are pockets of the market that perform exceptionally well. For example, I identified in another article. For this article, I screened the best-performing healthcare stocks year-to-date. I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (). A medical professional in scrubs providing care to a patient. Number of Hedge Fund Holders In Q4 2024: 6 Nutex Health Inc. (NASDAQ:NUTX) is a physician-led healthcare services company operating micro-hospitals, population health management, and real estate segments across the United States. The stock is up significantly so far in 2025 after the fourth-quarter and full-year 2024 earnings report, released in late March 2025, which showed total revenue nearly doubling to $479.9 million and net income swinging to $52.2 million from a $45.8 million loss the prior year. Adjusted EBITDA jumped over 1,000% to $123.7 million, and the hospital division saw visits rise by 17%. A key driver behind this explosive growth was Nutex Health Inc. (NASDAQ:NUTX)'s strategic shift in mid-2024 to aggressively pursue arbitration under the No Surprises Act for out-of-network claims. This resulted in much higher reimbursement rates per visit and an over 80% success rate in claims. The consensus price target of $80 implies 35.24% downside. Nutex Health Inc. (NASDAQ:NUTX) stock is up 289.84% year-to-date. Overall, NUTX ranks 4th on our list of healthcare stocks that are surging in 2025. While we acknowledge the potential of NUTX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than NUTX but that trades at less than 5 times its earnings, check out our report about this . READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Globe and Mail
09-04-2025
- Business
- Globe and Mail
Nutex Health Is a Rare, Undervalued Winner Amidst Market Turmoil
Wall Street had another rough day. Major stocks like Tesla (TSLA) and Nvidia (NVDA) were down significantly. Nutex Health (NUTX) stands out with a 100% technical 'buy' signal and impressive gains. Analysts and investors are bullish on NUTX, with multiple 'Strong Buy' ratings. Another Bad Day on Wall Street Everyone was still looking for the bottom, but today was not it. All five of the Top Trending Tickers on Barchart were down: SPDR S&P 500 ETF (SPY) (1.57%) Nasdaq QQQ Trust (QQQ) (1.80%) Nvidia (NVDA) (1.37%) Tesla (TSLA) (4.90%) Apple (AAPL) (4.98%) I didn't find a single S&P 500 Index ($SPX) stock that met my criteria so I had to dig a little deeper to find a chart I liked. Today's Featured Stock: Valued at only $416 million, Nutex Health NUTX is a physician-led healthcare services and operations company with 20 hospital facilities in eight states. The company is a component of the Medical Services Sector. What I'm Watching: I found today's Chart of the Day by using Barchart's powerful screening functions. I sorted for stocks with the highest technical buy signals, superior current momentum in both strength and direction, and a Trend Seeker 'buy' signal. I then used Barchart's Flipchart feature to review the charts for consistent price appreciation. NUTX checks those boxes. Since the Trend Seeker signaled a 'buy' on April 8, the stock has gained 18.96%. NUTX Stock Price vs. Daily Moving Averages: On the chart, you can note that the stock is trading above all of its daily moving averages and has rising prices on rising volume. Barchart Technical Indicators for NUTX Stock: Editor's Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the website when you read this report. These technical indicators form the Barchart Opinion on a particular stock. When a stock is trading above all of its daily moving averages and closes within 1% of its 52-week high, it won't take much to hit another new high. Nutex has a 100% technical 'buy' signal. The stock closed at $84.94 on April 8, which was its 52-week high NUTX has a weighted alpha of +411.42. The stock has gained 643.13% over the past year. Trend Seeker 'buy' signal intact. NUTX is trading above its 20-, 50- and 100-day moving averages. The stock has made 11 new highs and is up 90.19% in the last month. The 14-day Relative Strength Index is at 70.92% The technical support level at $80.31 Follow the Fundamentals: Note the projected increases in both revenue and earnings. Trailing price/earnings (P/E) ratio of 7.73x. Pays no dividend. Revenue is expected to grow 14.29% this year Earnings are estimated to decrease 24.34% this year Analyst and Investor Sentiment on Nutex: I don't buy stocks because everyone else is buying, but I do realize that if major firms and investors are dumping a stock, it's hard to make money swimming against the tide. It looks like not only Wall Street analysts, but also many of the popular investing advisory services, are bullish on this stock. Wall Street analysts issued two 'Strong Buy' opinions on the stock with price targets between $60 and $75. Value Line gives the stock an above average rating. CFRA's MarketScope gives the stock a 'Buy' rating. Morningstar thinks the stock is 26% undervalued and comments: 'Nutex Health Inc is assigned a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 26% discount to our quantitative fair value estimate of 102.38 USD per share; however, caution is warranted due to this estimate's high uncertainty rating.' Only one investor is following the stock on Motley Fool and he thinks the stock will beat the market. 766 investors monitor the stock on Seeking Alpha, which rates the stock a 'Strong Buy.' The Bottom Line: Healthcare stocks like Nutex are drawing investor attention and this may be a ground-floor opportunity. Additional disclosure: The Barchart Chart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance and reevaluate your stop losses at least on a weekly basis.
